Recent actions by the Department of Justice and DEA have partially rescheduled certain FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, effective late April 2026. This followed a December 2025 executive order directing expedited rulemaking. A new administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III begins June 29, 2026, and must conclude by July 15, 2026. Trader sentiment centers on the pace of this formal process, including potential legal challenges, public comments, and final rulemaking timelines that could extend into later 2026. Historical patterns of DEA scheduling reviews suggest delays remain possible despite the compressed schedule.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$758,943 Vol.
30. Juni
2%
31. Dezember
24%
$758,943 Vol.
30. Juni
2%
31. Dezember
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent actions by the Department of Justice and DEA have partially rescheduled certain FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, effective late April 2026. This followed a December 2025 executive order directing expedited rulemaking. A new administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III begins June 29, 2026, and must conclude by July 15, 2026. Trader sentiment centers on the pace of this formal process, including potential legal challenges, public comments, and final rulemaking timelines that could extend into later 2026. Historical patterns of DEA scheduling reviews suggest delays remain possible despite the compressed schedule.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen